MAYO CLINIC LABORATORIES

Test Definition: F5_IS

Factor V Inhib Scrn

Overview

Useful For

Detecting the presence of a specific factor inhibitor directed against coagulation factor V

Special Instructions

- Coagulation Guidelines for Specimen Handling and Processing

Method Name

Only orderable as part of a profile. For more information see:

5INHE / Factor V Inhibitor Evaluation, Plasma

ALUPP / Lupus Anticoagulant Profile, Plasma

ALBLD / Bleeding Diathesis Profile, Limited, Plasma

APROL / Prolonged Clot Time Profile, Plasma

Optical Clot-Based

NY State Available

Yes

Specimen

Specimen Type

Plasma Na Cit

Specimen Required

Only orderable as part of a profile. For more information see:

5INHE / Factor V Inhibitor Evaluation, Plasma

ALUPP / Lupus Anticoagulant Profile, Plasma

ALBLD / Bleeding Diathesis Profile, Limited, Plasma

APROL / Prolonged Clot Time Profile, Plasma

See Coagulation Guidelines for Specimen Handling and Processingin Special Instructions: Guidelines for Specimen Handling and Processing.

Reject Due To

Gross hemolysis	Reject
Gross lipemia	Reject
Gross icterus	Reject

Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Plasma Na Cit	Frozen (preferred)	14 days	

Clinical & Interpretive

Clinical Information

Patient plasma, normal pooled plasma (NPP), and a mixture of patient plasma and NPP are each tested for a specific factor, incubated at 37 degrees C for 1 hour, and then retested for the same factor. In addition, a new mixture of patient plasma and NPP is prepared using the incubated plasmas and tested after the 1 hour incubation. The percentage of the recovered factor for each individual plasma and mixture being tested is calculated and compared. The procedure demonstrates the effect of a specific coagulation factor inhibitor on that factor present in normal pooled plasma over a specific period of time.

An inhibitor directed against a coagulation factor may arise due to multiple exposures from transfusions in a patient deficient in that factor (as in the case of hemophiliacs), in response to certain disease states, or be drug-induced. Nonspecific inhibitors may also be present in patients that will prolong screening tests (eg, prothrombin time and activated partial thromboplastin time). This test is used to qualitatively identify an inhibitor to a specific coagulation factor.

Reference Values

Only orderable as part of a profile. For more information see:

5INHE / Factor V Inhibitor Evaluation, Plasma

ALUPP / Lupus Anticoagulant Profile, Plasma

ALBLD / Bleeding Diathesis Profile, Limited, Plasma

APROL / Prolonged Clot Time Profile, Plasma

Negative

Interpretation
An interpretive report will be provided when testing is completed.

Cautions
Occasionally, a potent lupus-like anticoagulant may cause false-positive testing for a specific factor inhibitor (eg, factor VIII or IX).

Clinical Reference
1. Bowie EJW, Thompson JH Jr, Didisheim P, Owen CA Jr: Mayo Clinic Laboratory Manual of Hemostasis. WB Saunders Company, 1971, pp 111-115

2. Laboratory Hematology Practice. Edited by K Kottke-Marchant. Wiley Blackwell Publishing, 2012

Performance

Method Description
The factor V inhibitor screen is performed on the Instrumentation Laboratory ACL TOP. The assay consists of measuring the factor V activity (prothrombin time based assay) before and after incubation of a mixture of normal plasma and patient's plasma for 1 hour at 37 degrees C. Interpretation of the presence or absence of the indication of a factor V inhibitor is determined by comparing the factor V activity results and the calculated expected values.(Owen CA Jr, Bowie EJW, Thompson JH Jr: The Diagnosis of Bleeding Disorders. Second edition. Little Brown and Company, 1975, pp 14-144; Meijer P, Verbruggen HW Spannagi M: Chapter 33: Clotting factors and inhibitors: Assays and Interpretation. In Laboratory Hematology Practice. Edited by K Kottke-Marchant. Wiley Blackwell Publishing, 2012, pp 435-446)

PDF Report
No

Specimen Retention Time
7 days

Performing Laboratory Location
Rochester

Fees & Codes

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

85335

LOINC® Information

Test ID	Test Order Name	Order LOINC Value
F5_IS	Factor V Inhib Scrn	81124-0

Result ID	Reporting Name	LOINC®
7808	Factor V Inhib Scrn	81124-0